At a glance
- Originator AstraZeneca
- Class Antineoplastics
- Mechanism of Action Intercellular signalling peptide and protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Solid tumours